Biocryst Pharmaceuticals Inc [BCRX] stock is trading at $8.53, up 2.16%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BCRX shares have lost -0.81% over the last week, with a monthly amount drifted -2.18%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biocryst Pharmaceuticals Inc [NASDAQ: BCRX] stock has seen the most recent analyst activity on April 29, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $20. Previously, Wedbush started tracking the stock with Outperform rating on February 25, 2025, and set its price target to $15. RBC Capital Mkts upgraded its rating to a Outperform and increased its price target to $10 on September 18, 2023. Jefferies upgraded its rating to a Buy but $11 remained the price target by the analyst firm on August 04, 2023. BofA Securities upgraded its rating to Buy for this stock on July 13, 2023, but kept the price target unchanged to $10. In a note dated February 22, 2023, Needham upgraded a Buy rating on this stock but restated the target price of $14.
Biocryst Pharmaceuticals Inc [BCRX] stock has fluctuated between $6.01 and $11.31 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Biocryst Pharmaceuticals Inc [NASDAQ: BCRX] shares were valued at $8.53 at the most recent close of the market. An investor can expect a potential return of 87.57% based on the average BCRX price forecast.
Analyzing the BCRX fundamentals
Biocryst Pharmaceuticals Inc [NASDAQ:BCRX] reported sales of 557.51M for the trailing twelve months, which represents a growth of 49.41%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at 0.1%, Pretax Profit Margin comes in at -0.06%, and Net Profit Margin reading is -0.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is 0.08 and Total Capital is 0.19. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.75.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.40 points at the first support level, and at 8.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.65, and for the 2nd resistance point, it is at 8.77.
Ratios To Look Out For
For context, Biocryst Pharmaceuticals Inc’s Current Ratio is 2.25. As well, the Quick Ratio is 2.22, while the Cash Ratio is 0.5. Considering the valuation of this stock, the price to sales ratio is 3.21.
Transactions by insiders
Recent insider trading involved HEGGIE THERESA, Director, that happened on Aug 13 ’25 when 70000.0 shares were purchased. Director, Hutson Nancy J completed a deal on Dec 13 ’24 to sell 7000.0 shares. Meanwhile, Director Hutson Nancy J bought 7000.0 shares on Dec 13 ’24.
